Demonstrated Safety
Included
2285 PATIENTSwith COPD in two 12-week efficacy studies and one 52-week, long-term safety study1
A total of
730 PATIENTSreceived YUPELRI 175 mcg once daily1
Adverse events from two 12-week placebo-controlled efficacy trials (N=813)1
Safety results from a 52-week, long-term trial with tiotropium (N=1055)1
Study design
YUPELRI was studied in a 52-week, open-label, active-control safety study in patients with COPD (YUPELRI 175 mcg/day, N=335; tiotropium 18 mcg/day, N=356)
Key findings
The adverse reactions reported in the long-term safety trial were consistent with those observed in the 12-week placebo-controlled studies
COPD=chronic obstructive pulmonary disease; LAMA=long-acting muscarinic antagonist.